The development of Codebeamer Copilot builds on Volkswagen Group’s adoption of Codebeamer to support software development ...

Rating, from 69 to 73.Please watch the video at Investors.com - Find Top Growth Stocks With The IBD Screen Of The DayThis ...

The results of CardinALS showed utreloxastat failed to meet its main and secondary goals, including several disease-related ...

Citi raised the firm’s price target on PTC Therapeutics (PTCT) to $32 from $26 and keeps a Sell rating on the shares. The firm updated the company’s model to reflect the Novartis collaboration, which ...

PTC Therapeutics, Inc. (PTCT) stock saw a modest uptick, ending the day at $52.07 which represents a slight increase of $8.19 or 18.66% from the prior close of $43.88. The stock opened at $52.08 and ...

I saw Wicked at the Fox in July 2023 with one of my best friends. It was a gift from my mom, my brother and his family for ...

Novartis licensed PTC's PTC518 Huntington's disease program and related molecules and will pay $1 billion upfront as well as other costs.

PTC Therapeutics (PTCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen ...

Novartis has entered a worldwide licensing and partnership agreement with PTC Therapeutics to develop PTC518, a potential ...

Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of PTC Inc. (NASDAQ:PTC – Free Report) in the ...

PTC (NASDAQ:PTC – Free Report) had its price objective upped by JPMorgan Chase & Co. from $200.00 to $210.00 in a report ...

PTC Therapeutics Inc. said a “highly competitive process with several parties involved” led to the deal centered on the ...